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MortalityAbstract Background: ARDS mortality is still high, many biomarkers had been used to predict
the mortality but they may have many drawbacks because of its validity, complications and cost.
Study design: Observational study was planned to evaluate the predictive role of serum uric acid
level in ARDS outcome. Mortality was the primary end-point while secondary endpoints included
total ICU stay, duration of mechanical ventilation and the presence or absence of complications.
Aim: The aim of this work is to study the role of serum uric acid level as an outcome predictor in
ARDS patients.
Patients and methods: Thirty three ARDS patients were enrolled in this study according to Ber-
lin 2012 deﬁnition. Patients with diabetes mellitus, chronic renal failure, cardiovascular disorders,
decompensated liver disease and known malignancies were excluded from the study. On admission
to ICU serum uric acid level was investigated.
Results: Sensitivity and speciﬁcity of uric acid as an outcome predictor at a cut off of 8.4 mg/dl
were 89% and 80% respectively; the area under curve was 0.88 with p value <0.001, mortality in a
high uric acid group that reported to be 86.7% was statistically signiﬁcant higher than the normal
uric acid group 38.9%.
Conclusion: Serum uric acid level at 8.4 mg/dl cut off point predicts mortality in ARDS patients
with 89% sensitivity and 80% speciﬁcity.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. All rights reserved.d.
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The acute respiratory distress syndrome (ARDS) was deﬁned
in 1994 by the American–European Consensus Conference
(AECC) [1]. Since then, issues regarding the reliability and
validity of this deﬁnition have emerged. Using a consensus
process, a panel of experts convened in 2011 (an initiative of
the European Society of Intensive Care Medicine endorsed
by the American Thoracic Society and the Society of Critical
Care Medicine) developed Berlin deﬁnition, focusing on feasi-
bility, reliability and validity [2]. Recent consensus group made
a number of changes to the previous American–European
Consensus Conference deﬁnition of ARDS which includes:
timing within one week of a known clinical insult or new or
worsening respiratory symptoms, chest imaging of bilateral
opacities not fully explained by effusions, lobar/lung collapse,
or nodules, the origin of edema and respiratory failure are not
fully explained by cardiac failure or ﬂuid overload which needs
objective assessment (e.g., echocardiography) to exclude
hydrostatic edema if no risk factor is present; and lastly oxy-
genation: mild PaO2/FIO2 6300–200 mmHg with PEEP or
CPAP P5 cmH2O; moderate: 6200–100 mmHg with PEEP
P5 cmH2O and severe: PaO2/FIO2 6100 mmHg with PEEP
P5 cmH2O [3].
ARDS is a life threatening respiratory condition character-
ized by hypoxemia and stiff lungs, without mechanical ventila-
tion most patients would die [4]. A complex network of
cytokines and other pro-inﬂammatory compounds initiate
and amplify the inﬂammatory response in acute respiratory
distress syndrome. New evidence indicates that it is not only
the production of pro-inﬂammatory cytokines that is impor-
tant, but also the balance between pro-inﬂammatory and
anti-inﬂammatory mediators [4]. Since its ﬁrst description in
1967, there have been a large number of studies addressing var-
ious clinical aspects of the syndrome (risk factors, epidemiol-
ogy and treatment) as well as studies addressing its
pathogenesis (underlying mechanisms, biomarkers and genetic
predisposition). The lack of therapeutic modalities is certainly
related to the complex pathogenesis of this syndrome with
multiple signaling pathways activated depending on the type
of lung injury. In addition, the lack of sensitive and speciﬁc
diagnostic criteria to diagnose ARDS has hampered progress
[3]. Serum uric acid is the ﬁnal product of purine degradation
[5], which increases signiﬁcantly during hypoxia [6]. Increased
level of uric acid in respiratory disorders, including obstructive
sleep apnea, pulmonary hypertension and COPD was reported
in several studies [7,8].
Impaired pulmonary function reduces oxygen intake result-
ing in tissue hypoxia which is more prominent during acute
exacerbation in COPD, this may lead to increased circulating
uric acid levels originating from both lung and peripheral tis-
sue damage [9]. Elevated uric acid levels have been associated
with the presence of systemic inﬂammation [10] and increased
cardiovascular risk [11]. Elevated uric acid levels have been
associated with increased levels of inﬂammatory markers
(e.g. CRP and interleukin-6) [12].
ARDS related mortality is still high, many biomarkers had
been used to predict mortality but they may have many draw-
backs because of its validity, complications and cost. To date,
as far as we know, no studies have evaluated the role of serum
uric as an outcome predictor in ARDS patients. Therefore, thiscohort observational study was conducted to evaluate the pos-
sible role of serum uric acid as a biomarker for outcome pre-
diction in ARDS patients. Mortality was the primary end-
point while secondary endpoints included total ICU stay,
duration of mechanical ventilation and presence or absence
of complications.
Patients and methods
After approval from the departmental ethics committee, this
cohort observational study was conducted in the pulmonary
critical care unit, Mansoura University Hospitals during the
period from July 2013 to August 2014 including 11 females
and 22 males with ages ranging from 18 to 50 years suffering
from ARDS according to the Berlin 2012 deﬁnition, which is
based on history, X-ray opacities, exclusion of cardiac causes
of pulmonary edema and PaO2/FIO2 ratio [1]. Patients with
diabetes mellitus, chronic renal failure, cardiovascular disor-
ders, decompensated liver disease and known malignancies
were excluded from the study. Plain chest X-ray, trans-thoracic
echocardiography was done to exclude patients with cardio-
vascular disorders.
Admission APACHEII score was calculated. Blood sam-
ples were collected from each patient on admission and prior
to initiation of any treatment for basic serum uric acid and
standard laboratory measurements (complete blood count,
serum creatinine and blood gases). Uric acid was measured
using enzymatic colourimetric method. Uric acid values above
or equal to 6.4 mg/dl were considered the high uric acid group
and below it were the normal uric acid group. Mortality rate
was reported. Total ICU stay, duration of mechanical ventila-
tion and presence or absence of complications were also
reported, consent was taken from ﬁrst-degree patient relative.
Statistical analysis
Statistical analysis was conducted by using SPSS (version 17,
Chicago, IL). For continuous variables, data were tested for
normal distribution using the Kolmogorov–Smirnov test.
The description of the data was done in the form of
mean ± SD for quantitative data and frequency and propor-
tion for qualitative data. The analysis of the data was done
to test statistically signiﬁcant difference between groups. For
quantitative date, unpaired Student’s t-test was used to com-
pare between two groups. Chi square test was used for quali-
tative data. Receiver operating characteristics (ROC) curve
analysis was performed for the evaluation of the sensitivity
and speciﬁcity of serum uric acid level and PaO2/FIO2 in pre-
dicting ARDS mortality. Correlations were performed with
Pearson’s rank correlation coefﬁcient. For all tests, statistical
signiﬁcance was considered when p< 0.05.
Results
Comparing data in high and normal uric acid groups, there
was no statistically signiﬁcant difference as regards age in both
high (P6.4 mg/dl) and normal uric acid (<6.4 mg/dl) groups
32.6 ± 8 and 32.7 ± 9 respectively, p value of 0.97 (Table 1).
Statistically signiﬁcant lower APACHEII was reported in high
uric acid group 27.1 ± 3.8 in comparison with normal uric
Table 1 Comparison between high and normal serum uric acid ARDS patients. Data are expressed as mean ± standard deviation,
number and percentage.
High uric acid group P6.4 mg/dl (n= 15) Normal uric acid group <6.4 mg/dl (n= 18) t P-Value
Age (years) 32.6 ± 8 32.7 ± 9 0.041 0.968
APACHEII 27.1 ± 3.8 42.3 ± 7.3 7.309 <0.001*
PaO2/FIO2 (mmHg) 94.1 ± 38.4 159.3 ± 57.2 3.761 <0.001
*
Outcome v2 = 7.187 0.007*
Died 13 (86.7%) 7 (38.9%)
Survived 2 (13.3%) 11 (61.1%)
Etiology v2 = 8.460 0.037*
Near 5 (33.3%) 14 (77.8%)
Drowning 4 (26.7%) 0 (0%)
Aspiration 6 (40%) 4 (22.2%)
Pneumonia
Duration/day
Ventilation 7.9 ± 1.4 13.3 ± 2.6 7.296 <0.001*
ICU stay 10.1 ± 1.4 16.5 ± 2.3 9.247 <0.001*
MODS 10 (66.7%) 4 (22.2%) v2 = 2.347 0.012*
APACHEII: Acute Physiology and Chronic Health Evaluation; MODS: Multiple Organ Dysfunction Syndrome; FIO2: Fraction of Inspired
Oxygen.
* Denotes signiﬁcant test.
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Figure 1 Outcome in high versus normal uric acid group.
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the PaO2/FIO2 was statistically signiﬁcant lower 94.1 ± 38.4
in high uric acid group than 159.3 ± 57.2 in normal uric acid
group with p value 0.001 (Table 1). On the other side, the mor-
tality in high uric acid group was statistically signiﬁcant higher
than the normal uric acid group 86.7% and 38.9% respec-
tively; p value was 0.007 (Table 1 and Fig. 1). Regarding the
etiology of ARDS, near drowning represents 33.3% in the high
uric acid group compared to 77.8% in the normal uric acid
group; 26.66% gastric aspiration was present in only high
group and none in the normal uric acid group while severe
pneumonia represents 40% in high compared to 22.2% in
the normal uric acid group (Table 1). The duration of ventila-
tion was statistically signiﬁcantly lower in the high uric acid
group (7.9 ± 1.4) compared to the normal uric acid group
(13.3 ± 2.6) also the total ICU stay was statistically signiﬁ-
cantly lower in the high (10.1 ± 1.4) compared to
(16.5 ± 2.3) normal uric acid group (Table 1). Multiple organ
dysfunction syndrome was encountered more in the high uric
acid group 66.7% than the normal uric acid group 22.2% it
was statistically signiﬁcant; p value 0.012 (Table 1).Comparing data between survived versus dead, there was
no statistically signiﬁcant difference for age in both survived
and dead 32.0 ± 8.6 and 33.2 ± 8.4 respectively p value of
0.684 (Table 2). While the APACHEII was statistically signif-
icant lower in dead one (29.6 ± 6.3) than survived one
(42.3 ± 8.5); p was <0.001 (Table 2). Furthermore, the
PaO2/FIO2 was statistically signiﬁcant lower 87.7 ± 28.1 in
died group than 179.9 ± 44.8 in the survived group p was
<0.001 (Table 2). On the other side, the uric acid level in dead
one 8.8 ± 2.8 mg/dl was statistically signiﬁcant higher than
5.0 ± 1.8 mg/dl in survived one p was <0.001 (Table 2). As
regards the etiology of ARDS, near drowning represents
92.30% in survived compared to (35%) died groups, gastric
aspiration represents 20% in dead and no one survived had
gastric aspiration. Pneumonia was found in 45% of died group
compared to only 7.69% in survived group (Table 2). In spite
of the duration of ventilation being shorter in dead one
(9.9 ± 3.2) days compared to survived (12.1 ± 3.4) it was
non-signiﬁcant p= 0.06 (Table 2). In addition, the total
ICU stay was statistically signiﬁcant shorter in died group
(12.1 ± 3.2) compared to (15.4 ± 3.7) survived p value was
0.01 (Table 2). Multiple organ dysfunction syndrome was
encountered more in dead 60% than survived 15.4% it was
statistically signiﬁcant; p value was <0.001 (Table 2). There
was a statistically signiﬁcant negative correlation between uric
acid and APACHEII 0.84 p value <0.001 and the same neg-
ative correlation between uric acid and PaO2/FIO2 0.68; p
value was <0.001 (Table 3 and Figs. 2a and 2b).
Finally, the sensitivity and speciﬁcity of uric acid as an out-
come predictor at cut off 8.4 mg/dl were 89% and 80% respec-
tively; the area under curve was 0.88 with a p value of <0.001,
while the sensitivity and speciﬁcity of PaO2/FIO2 at 99 cut off
were 100% and 83% respectively; the area under the curve was
0.97 with a p value of <0.001 (Table 4 and Fig. 3a and b).
Discussion
The ﬁndings of this cohort observational study demonstrated
that high serum uric acid level was associated with higher
Table 2 Comparison between survived and died in ARDS patients. Data are expressed as mean ± standard deviation, number and
percentage.
Survived group (n= 13) Died group (n= 20) t P-Value
Age (years) 32.0 ± 8.6 33.2 ± 8.4 0.411 0.684
APACHEII 42.3 ± 8.46 29.6 ± 6.3 4.916 <0.001*
Uric acid (mg/dl) 5.0 ± 1.8 8.8 ± 2.8 4.738 <0.001*
PaO2/FIO2 (mmHg) 179.9 ± 44.8 87.7 ± 28.1 7.211 <0.001
*
Etiology 9.989 0.019*
Near drowning 12 (92.30%) 7 (35%)
Aspiration 0 (0%) 4 (20%)
Pneumonia 1 (7.69%) 9 (45%)
Duration/day
Ventilation 12.1 ± 3.4 9.9 ± 3.2 1.885 0.069
ICU stay 15.4 ± 3.7 12.1 ± 3.2 2.748 0.01*
MODS 2 (15.4%) 12 (60%) v2 = 15.632 <0.001*
APACHEII: Acute Physiology and Chronic Health Evaluation; MODS: Multiple Organ Dysfunction Syndrome; FIO2: Fraction of Inspired
Oxygen.
* Denotes signiﬁcant test.
Table 3 Correlation between uric acid on one side and
APACHII and PaO2/FIO2 on the other side.
Uric acid level
rs coeﬃcient P-Value
APACHEII 0.84 <0.001*
PaO2/FIO2 0.68 <0.001*
* It indictes statistically signiﬁcant.
Figure 2a Correlation between uric acid and APACHII.
Figure 2b Correlation between uric acid and PaO2/FIO2.
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tiple organ dysfunction syndrome. Serum uric acid at 8.4 mg/
dl cut off point predicts mortality in ARDS patients with
89% sensitivity and 80% speciﬁcity.
Uric acid levels are inﬂuenced by several factors including
cardiovascular disease, food intake, alcohol consumption,
renal dysfunction and genetic disorders of purine metabolism
[11].
In the evaluation of serum uric acid levels we need to take
into account that this metabolite is the end product of purinedegradation, which increases in a very sensitive but nonspeciﬁc
way in several forms of tissue damage and inﬂammation [13].
It was suggested that tissue injury may cause sterile inﬂam-
mation and several mediators such as uric acid, ATP, high
mobility group box1 protein, heat shock protein 70, lysophos-
phatidic acid and others have been identiﬁed. These danger
signals may be produced after lung damage, triggering inﬂam-
mation, remodeling and ﬁbrosis [14]. ARDS represents a ster-
eotypic response to many different inciting insults. ARDS is a
life threatening respiratory condition characterized by hypox-
emia [4]. Serum uric acid levels increases signiﬁcantly during
hypoxia [7–9]. Elevated uric acid levels have been associated
with the presence of systemic inﬂammation [12].
APACHEII was statistically signiﬁcant lower in ARDS
patients with uric acid P6.4 mg/dl group than those with uric
acid <6.4 mg/dl group, besides our ﬁnding that APACHEII
was statistically signiﬁcantly lower in patients who died than
survived. Not only that but also, the signiﬁcant negative corre-
lation between uric acid and APACHEII; i.e. lower APAC-
HEII which indicates the more severity of illness in admitted
ARDS patients had a higher uric acid level. Data from the
Table 4 Sensitivity and speciﬁcity of both uric acid and PaO2/FIO2 as outcome predictors.
Cut oﬀ point (mmHg) Area under the curve P-Value Sensitivity Speciﬁcity
Uric acid 8.4 0.88 <0.001 89% 80%
PaO2/FIO2 99 0.97 <0.001 100% 83%
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Figure 3 (a) ROC curve for uric acid and (b) ROC curve for
FIO2.
Role of serum uric acid in acute respiratory distress syndrome 201large ECLIPSE cohort study in COPD exacerbation suggested
that the frequent-exacerbation phenotype is more common in
more severe disease and this may, in part, explain the associa-
tion between high serum uric acid levels with disease severity
and exacerbation frequency [15].
The PaO2/FIO2 was statistically signiﬁcant lower in the
high uric acid group than in normal uric acid group. Addition-
ally, PaO2/FIO2 was statistically signiﬁcant lower in dead than
in survived one, moreover, there was a statistically signiﬁcant
negative correlation between uric acid and PaO2/FIO2, mean-
ing that ARDS patients with more hypoxemia had a higher
serum uric acid level as well as both correlated inversely. Theseﬁndings were explained by Bartziokas and his associates [7]
who found that serum uric acid which is the ﬁnal product of
purine degradation, increases signiﬁcantly during hypoxia
which is a hall mark feature in ARDS patients. Also, Fabbri
and Rabe [9] reported that impaired pulmonary function
reduces oxygen intake resulting in tissue hypoxia which was
more prominent during acute exacerbation in COPD and this
may lead to increased circulating uric acid levels originating
from both lung and peripheral tissue damage. Elevated uric
acid levels had been associated with increased levels of inﬂam-
matory markers (e.g. CRP and interleukin-6) [12] which were
also increased in ARDS patients. Therefore, not only PaO2/
FIO2 triage ARDS patients into mild, moderate and severe,
but also predict poor outcome whenever it is low. In our study
the sensitivity and speciﬁcity of PaO2/FIO2 at 99 cut off were
100% and 83% respectively.
The reported mortality rate of acute respiratory distress
syndrome was from 40 to 60% [16] which was almost matched
with the results of 20 patients out of 33 mortality in our study
(60.6%), that mortality was statistically signiﬁcant higher in
high uric group (86.66%) compared to only (38.88%) in the
normal group, also the serum level of uric acid in those who
died was statistically signiﬁcant higher than in survived ARDS
patients which may be explained by the study of Filippatos and
his coworker, who showed that hyperuricaemia is associated
with poor outcomes in heart failure patients without chronic
kidney disease but not in those with chronic kidney disease,
suggesting that hyperuricaemia may predict poor outcomes
when it is related to increased xanthine oxidase activity, but
not due to impaired renal excretion of uric acid [17]. As far
as we know, no available studies matched hyperuricaemia with
mortality in ARDS patients but indirectly most ARDS
patients do not die without passing into the journey of heart
failure. Patients with pneumonia had higher mortality than
near drowning patients. On the other side of the coin, the cur-
rent study displayed that multiple organ dysfunction syndrome
was encountered more in high uric acid group than normal
group and its incidence was statistically signiﬁcant higher in
dead compared to survived ARDS patients which may add
to the concept of severe ARDS; more hypoxemia; more multi-
ple organ dysfunction syndrome and more death.
In the present study, the association between high serum
uric acid and lower APACHEII score; lower PaO2/FIO2;
higher incidence of organ failures and higher mortality sug-
gests an important role of serum uric acid as a prognostic bio-
marker in ARDS, further studies are needed to consolidate our
ﬁndings.
The present study was not without limitations; ﬁrst, a small
number of studied ARDS patients (only 33 patients), second,
ARDS etiology was mono dimensional; mainly of medical
rather than surgical, direct rather than indirect. Third, we
did not measure uric acid at different times along the journey
of admission for our patient because the notion of mortality
prediction circumvents this issue. The previous limitations
202 M. Elshafey et al.make back generalization difﬁcult for this preliminary study.
Further studies are warranted for more convenience.
The present study concluded that serum uric acid at 8.4 mg/
dl cut off predicts mortality in ARDS patients with 89% sen-
sitivity and 80% speciﬁcity. The presence of higher mortality,
low PaO2/FIO2 and low APACHEII in patients with higher
serum uric acid level encourages us to pay attention to the
importance of serum uric acid which is one of the routine met-
abolic proﬁles in pulmonary critical care practice and because
it is a rapid, easy and cheap test sparing money funding costly
markers and effort waiting tedious results we can adopt it as
one of the valuable outcome predictors for that still fatal
ARDS problem.
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